Palmitoyl Tripeptide-1: What the Research Actually Shows

Educational Notice

This article is written for researchers, formulators, clinicians, and informed consumers seeking to understand the published evidence on palmitoyl tripeptide-1. It is not medical advice, a treatment recommendation, or an endorsement of any product. Palmitoyl tripeptide-1 is a cosmetic ingredient — not a pharmaceutical drug — and is not evaluated by the FDA for safety or efficacy. Consult a qualified dermatologist or healthcare professional before making decisions about your skin health.

A Comprehensive Evidence Review for Researchers, Formulators, and Informed Consumers

Palmitoyl tripeptide-1 is one of those cosmetic ingredients that most people have used without knowing it. It is one of the two active components of Matrixyl 3000 — arguably the most widely sold cosmetic peptide blend in the world — yet it is almost never discussed as a standalone ingredient. If a product lists “palmitoyl tripeptide-1” on its INCI label, it either contains Matrixyl 3000 (alongside palmitoyl tetrapeptide-7) or contains the peptide in isolation. Understanding what palmitoyl tripeptide-1 is, what it does independently, and what portion of Matrixyl 3000’s clinical evidence is attributable specifically to it requires separating the compound from the formulation it almost always travels with.

Palmitoyl tripeptide-1 contains the GHK amino acid sequence — the same tripeptide core found in GHK-Cu (glycyl-L-histidyl-L-lysine copper complex), the most extensively studied cosmetic peptide in the skin literature. The difference is significant: GHK-Cu chelates copper as an integral part of its mechanism, with the copper ion playing an active role in tissue remodeling and enzyme activation. Palmitoyl tripeptide-1 does not chelate copper — the GHK sequence here functions as a matrikine signal, and the palmitoyl chain functions as a lipophilic delivery anchor. Same tripeptide backbone, different chemistry, different primary mechanism, different evidence base.

This article examines palmitoyl tripeptide-1 as a standalone ingredient — its mechanism, its evidence base, the distinction from GHK-Cu, and what all three delivery routes (topical, microneedling, and subcutaneous injection) look like in terms of evidence and rationale.

Quick Facts

INCI Name

Palmitoyl Tripeptide-1

Peptide Sequence

Pal-GHK (palmitoyl-glycine-histidine-lysine)

Mechanism Class

Signal peptide (matrikine) — collagen I, III, and fibronectin stimulation via TGF-β pathway

Evidence Tier

Pilot / Limited Human Data (primarily as component of Matrixyl 3000)

Regulatory Status

Cosmetic ingredient — not a drug. No FDA approval or evaluation required.

WADA Status

Not prohibited

Molecular Weight

~583 Da — near the 500 Da passive penetration threshold; palmitoyl chain improves lipid barrier affinity

Found In

Matrixyl 3000® (with Palmitoyl Tetrapeptide-7); also available as standalone ingredient

The research moves fast. We read all of it so you don’t have to.

New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.

Subscribe to Peptidings Weekly

What Is Palmitoyl Tripeptide-1?

Palmitoyl tripeptide-1 (Pal-GHK) is a palmitoylated synthetic tripeptide consisting of glycine, histidine, and lysine — the GHK sequence — with a C16 palmitoyl fatty acid chain attached to the N-terminus. It is one of the two active components of Matrixyl 3000 (the other being palmitoyl tetrapeptide-7/Rigin), but it also exists and is sold as a standalone cosmetic active.

Its primary mechanism is matrikine signaling: the GHK sequence is derived from the C-terminal region of the alpha-2 chain of collagen I, and is released as a natural degradation fragment when the extracellular matrix is broken down by matrix metalloproteinases. This fragment acts as an endogenous wound-repair signal, activating fibroblasts via the TGF-β pathway to upregulate synthesis of collagen I, collagen III, fibronectin, and elastin. Palmitoyl tripeptide-1 mimics this signal, delivering the GHK matrikine message without requiring actual collagen degradation to initiate the repair response.

The palmitoyl chain serves the same delivery purpose as in other palmitoylated cosmetic peptides — it increases lipophilicity, improving passive penetration through the stratum corneum’s lipid-rich barrier, which would otherwise be largely impermeable to the hydrophilic GHK tripeptide alone.

Origins and Development

The GHK tripeptide has a long research history. Loren Pickart identified GHK as an endogenous copper-binding tripeptide in human plasma albumin in 1973, and subsequently characterized its role in tissue remodeling, wound healing, and the stimulation of collagen synthesis. Pickart’s research on GHK-Cu — the copper complex — generated a substantial body of work on the peptide’s biological activities across multiple decades. This research established the GHK sequence as biologically active and laid the foundation for cosmetic applications.

Sederma developed palmitoyl tripeptide-1 as part of the Matrixyl 3000 formulation, pairing the GHK-derived matrikine signal with the anti-inflammatory peptide Rigin (palmitoyl tetrapeptide-7). The combination was designed based on the rationale that collagen stimulation and inflammation control address complementary aspects of skin aging. Palmitoyl tripeptide-1 is also available as a standalone ingredient from multiple suppliers — particularly relevant for formulators who want the matrikine signal without the full Matrixyl 3000 combination, or who pair it with different anti-inflammatory actives.

The GHK Connection: Palmitoyl Tripeptide-1 vs. GHK-Cu

The shared GHK sequence creates meaningful confusion between palmitoyl tripeptide-1 and GHK-Cu. They are related but distinct compounds with meaningfully different chemistry and partially different mechanisms.

Palmitoyl Tripeptide-1 (Pal-GHK) GHK-Cu (Copper Tripeptide-1)
Core sequence GHK (same) GHK (same)
Modification Palmitoyl chain at N-terminus — lipophilic delivery anchor for stratum corneum penetration Copper(II) chelation — Cu²⁺ is integral to mechanism, not just delivery
Primary mechanism Matrikine signaling via TGF-β → collagen I/III, fibronectin upregulation Matrikine signaling + copper delivery for lysyl oxidase, SOD, and wound healing enzyme activation
Evidence base Primarily as component of Matrixyl 3000; limited standalone clinical data Broader — standalone human studies, multiple independent publications, decades of Pickart research
Route optimization Topical — palmitoyl chain designed for stratum corneum lipid penetration Topical and injectable; copper complex is water-soluble, different penetration profile

Plain English

Palmitoyl tripeptide-1 and GHK-Cu share the same three amino acids but are chemically different compounds. Think of it this way: GHK-Cu carries copper as part of its job description; palmitoyl tripeptide-1 carries a fatty acid chain to help it get through skin. They send a similar “make collagen” signal to fibroblasts, but GHK-Cu does more on top of that through the copper it delivers. GHK-Cu also has more independent research behind it.

Mechanism of Action

Palmitoyl tripeptide-1 acts primarily through matrikine signaling. The GHK sequence is recognized by fibroblast surface receptors as a collagen degradation fragment — a natural damage signal in the extracellular matrix. Upon receptor binding, it activates the TGF-β/Smad signaling cascade, which upregulates transcription of genes encoding type I and type III procollagen, fibronectin, and elastin. It may also modulate matrix metalloproteinase (MMP) activity, reducing collagen degradation while simultaneously stimulating synthesis — a dual effect on net collagen balance.

In vitro studies have confirmed these effects in human dermal fibroblast cultures at relevant concentrations. The GHK sequence activates integrin receptors (particularly β1 integrins) and may also signal through decorin-mediated TGF-β activation, adding a second mechanistic pathway to the collagen-stimulating response. The biochemical evidence for these cellular effects is well-established and has been characterized across multiple independent laboratory systems — a stronger mechanistic foundation than many cosmetic peptides.

Plain English

The GHK sequence activates fibroblasts through more than one pathway simultaneously — it’s not just a simple on/off collagen switch. In cell studies this produces both more collagen being made and less collagen being broken down. Whether this dual effect translates to living human skin at topical concentrations is the central unanswered question.

What palmitoyl tripeptide-1 does not do — in contrast to GHK-Cu — is deliver copper. The palmitoyl chain replaces the copper-binding function of the native GHK-Cu complex with a lipophilic delivery function. This means palmitoyl tripeptide-1 activates the matrikine signaling pathway but does not provide the copper cofactor activity of GHK-Cu — no lysyl oxidase activation via copper, no superoxide dismutase potentiation, no copper-dependent wound healing enzyme support. The two compounds are best understood as overlapping but non-interchangeable — both signal collagen synthesis through GHK, but GHK-Cu does additional things through its copper payload that palmitoyl tripeptide-1 does not.

Key Research Areas and Studies

In Vitro Mechanistic Studies

Multiple in vitro studies have confirmed palmitoyl tripeptide-1’s ability to stimulate procollagen I and III synthesis in human dermal fibroblasts, with dose-dependent responses observed across several cell culture systems. Studies have also demonstrated upregulation of fibronectin and inhibition of MMP-1 (interstitial collagenase) at tested concentrations, supporting the proposed dual synthesis/degradation mechanism. The GHK sequence’s role in TGF-β and integrin signaling has been characterized by independent academic researchers — Pickart’s body of work and subsequent independent citations provide a more robust mechanistic foundation for the GHK sequence than is typical for proprietary cosmetic peptide sequences.

Clinical Evidence: Primarily Through Matrixyl 3000

The most important clinical evidence for palmitoyl tripeptide-1 comes from the Robinson 2005 Matrixyl 3000 study — 23 women, 3% formulation (containing both palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7), 60 days, showing significant wrinkle reduction versus vehicle control. This is clinical evidence for the combination, not for palmitoyl tripeptide-1 alone. Separating the contribution of palmitoyl tripeptide-1 specifically from that of palmitoyl tetrapeptide-7 is not possible from the Robinson 2005 data.

Standalone clinical data for palmitoyl tripeptide-1 is limited. Some multi-peptide formulation studies have included palmitoyl tripeptide-1 as a component, but these multi-ingredient designs do not allow ingredient-level attribution. A published in vitro study by Snap et al. (Sederma technical data) demonstrated dose-dependent procollagen I stimulation in fibroblasts that significantly exceeded the effect of the palmitoyl chain alone or the unmodified GHK tripeptide, supporting the value of the palmitoylated form. This is in vitro data, not clinical outcome data, but it confirms that the palmitoylation meaningfully enhances the biological effect compared to the unmodified peptide.

Evidence note: Palmitoyl tripeptide-1 has strong mechanistic and in vitro support, and reasonable clinical evidence as a component of Matrixyl 3000. It does not have a standalone clinical trial with the design quality of the Robinson 2003 original Matrixyl study or the Robinson 2005 Matrixyl 3000 study. The clinical evidence tier reflects the combination context in which most human data was generated.

Common Claims versus Current Evidence

Claim What the Evidence Shows Verdict
“Stimulates collagen production” Well-supported in vitro; GHK sequence has one of the stronger independent mechanistic foundations among cosmetic matrikine peptides. Clinical evidence comes primarily from Matrixyl 3000 combination studies. Supported in vitro; clinical inference reasonable from combination data
“Same as GHK-Cu” Shares GHK sequence but is a chemically distinct compound. GHK-Cu chelates copper as a mechanistic component; Pal-tripeptide-1 uses palmitoylation for topical delivery without copper activity. Different chemistry, partially overlapping but not identical mechanisms, different evidence bases. Incorrect — related but distinct compounds
“Clinically proven as a standalone” No standalone clinical trial comparable to the Robinson 2003 original Matrixyl study. Most human data comes from Matrixyl 3000 combination studies where separating individual ingredient contributions is not possible. Overstated — combination evidence, not standalone
“Works through injection” No published injection data. Palmitoylation is a topical delivery strategy — it improves stratum corneum lipid barrier penetration, not systemic distribution. SC injection bypasses the mechanism for which the compound is chemically designed. No evidence; chemistry argues against SC rationale

The research moves fast. We read all of it so you don’t have to.

New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.

Subscribe to Peptidings Weekly

The Human Evidence Landscape

Palmitoyl tripeptide-1 sits in an unusual position in the Cluster G evidence landscape. Its mechanistic foundation — rooted in Pickart’s GHK research and multiple independent in vitro characterizations — is stronger than most proprietary cosmetic peptides. Its standalone clinical evidence is weaker, because it is almost always studied in combination with palmitoyl tetrapeptide-7 as Matrixyl 3000. The Robinson 2005 Matrixyl 3000 study is clinical evidence for palmitoyl tripeptide-1 functioning in a combination — a reasonable inference of activity, but not an isolated demonstration.

For formulators, this creates a practical question: is palmitoyl tripeptide-1 worth including as a standalone, or only as part of the Matrixyl 3000 combination? The mechanistic case for the standalone is solid. The anti-inflammatory activity of palmitoyl tetrapeptide-7 that Matrixyl 3000 adds is a meaningful additional mechanism — reducing inflammatory matrix degradation while palmitoyl tripeptide-1 stimulates synthesis. For formulations that include other anti-inflammatory actives (niacinamide, tranexamic acid, centella asiatica), the case for standalone palmitoyl tripeptide-1 is stronger than in formulations with no anti-inflammatory component.

Safety, Risks, and Limitations

Topical Safety

Palmitoyl tripeptide-1 has an excellent topical safety profile, consistent with other palmitoylated cosmetic peptides and with the broader Matrixyl 3000 safety record across decades of widespread commercial use. Contact sensitization is rare. No serious adverse events have been reported in the published literature. The ingredient is well-tolerated across skin types and is compatible with standard cosmetic formulation components.

Microneedling Safety Considerations

Microneedling with palmitoyl tripeptide-1 solution follows the same rationale as Matrixyl 3000 microneedling — dermal fibroblast targets are at depths directly accessible to microneedling devices, making the delivery approach mechanistically appropriate. No palmitoyl tripeptide-1-specific microneedling study exists. Sterility of cosmetic-grade source material remains the primary safety concern. Because palmitoyl tripeptide-1 is frequently purchased as a powder or concentrated solution by formulators and self-experimenters, source material quality and reconstitution sterility are particularly important variables.

Subcutaneous Injection Safety

No published SC injection data exists. The palmitoyl chemistry is designed for topical lipid barrier interaction, not systemic distribution. SC injection of a palmitoylated peptide would result in systemic distribution without the lipid-anchoring delivery mechanism for which the compound is chemically optimized. Cosmetic-grade palmitoyl tripeptide-1 is not manufactured to pharmaceutical sterility standards. The SC injection risk-benefit analysis is the same as for Matrixyl 3000: no evidence, weak rationale based on chemistry, non-sterile source material.

Legal and Regulatory Status

Palmitoyl tripeptide-1 is a cosmetic ingredient regulated under standard cosmetic frameworks in the US and EU. No FDA pre-market approval or clinical trial data is required. In the EU, standard cosmetic safety assessment requirements apply under Regulation EC 1223/2009. The ingredient is available from multiple suppliers as a standalone active — not exclusively through Sederma as part of the Matrixyl 3000 blend. Generic palmitoyl tripeptide-1 from reputable cosmetic ingredient suppliers is chemically equivalent to the Sederma version at equivalent concentrations.

WADA status: not prohibited. No restrictions for athletes subject to anti-doping testing.

Research Protocols and Formulation Considerations

Concentration: The Matrixyl 3000 clinical study used a 3% combination formulation — the palmitoyl tripeptide-1 component within that is approximately half the active peptide content by weight of the blend. Standalone use recommendations from suppliers generally suggest 1–3% in the final formulation. As with all cosmetic peptides, commercial products often contain significantly less.

Stability: Palmitoyl tripeptide-1 is stable across pH 4.5–7.5, compatible with most standard cosmetic actives at these pH levels. It degrades in highly acidic formulations (pH below 4) — the same vitamin C compatibility consideration applies as for other cosmetic peptides.

Standalone vs. combination: Formulators choosing between standalone palmitoyl tripeptide-1 and Matrixyl 3000 are essentially choosing between a single matrikine signal and a dual matrikine-plus-anti-inflammatory approach. If the formulation already contains strong anti-inflammatory actives (niacinamide, tranexamic acid, centella asiatica, azelaic acid), adding standalone palmitoyl tripeptide-1 at 2–3% may be as effective as using the full Matrixyl 3000 blend. If the formulation lacks anti-inflammatory components, Matrixyl 3000 (which includes Rigin’s IL-6 suppression) is the more complete anti-aging approach.

GHK-Cu combination: Some formulators combine palmitoyl tripeptide-1 with GHK-Cu to provide both the palmitoylated matrikine signal and the copper-dependent enzyme activation. This combination addresses collagen synthesis from two directions simultaneously and has mechanistic logic. No published clinical trial of this specific combination exists, but the mechanisms are complementary and non-redundant.

Dosing and Delivery: What the Research Shows

Topical Application

Clinical evidence for topical palmitoyl tripeptide-1 comes from the Matrixyl 3000 combination studies, primarily Robinson 2005 at 3% total combination, applied twice daily for 60 days. For standalone use, supplier recommendations suggest 1–3% in finished formulation, twice daily on clean skin before heavier emollients. The same general principle applies as to all collagen-stimulating matrikines — effects accumulate over 8–12 weeks of consistent use and may be somewhat durable beyond the application period due to structural collagen changes, though this has not been formally studied for this specific compound.

Microneedling / Stamping

Microneedling with palmitoyl tripeptide-1 is mechanistically motivated — dermal fibroblasts at 0.5–2.0 mm depth are the target cells, and bypassing the stratum corneum barrier via microchannels improves delivery to this depth. No palmitoyl tripeptide-1-specific microneedling trial exists. Community practice involves dissolving peptide powder in bacteriostatic water at 1–3% concentration for use at 0.5–1.5 mm depth, with standard post-procedure care. Palmitoyl tripeptide-1 is frequently included in DIY microneedling solutions alongside Matrixyl 3000 or other collagen-stimulating peptides.

Subcutaneous Injection

No published data. The palmitoyl delivery chemistry is designed for topical lipid barrier penetration, not systemic delivery. SC injection distributes the compound throughout the body rather than concentrating it at dermal fibroblasts. The pharmacological argument is the same as for all palmitoylated cosmetic peptides: the modification that makes these compounds effective topically is not a systemic delivery enhancer. No evidence, weak rationale, non-sterile source material.

Delivery Routes in Self-Experimentation Communities

Route Community Use Evidence Key Risks
Topical serum/cream Common — as component of Matrixyl 3000 formulations and standalone; frequently in DIY serum formulations Combination clinical data (Robinson 2005); strong in vitro mechanistic data; GHK sequence independently characterized Low — excellent safety record; source quality varies for standalone powder purchases
Microneedling / stamping Common — frequently included in DIY microneedling solutions, often with Matrixyl 3000 and other matrikines No specific trials; dermal fibroblast targeting is mechanistically appropriate for microneedling depths Moderate — sterility of source material; powder quality varies by vendor
SC injection Uncommon No published data Higher — palmitoyl chemistry is a topical delivery strategy; systemic distribution is not the intended mechanism; non-sterile source material

In the self-experimentation community, palmitoyl tripeptide-1 is understood primarily as “the GHK peptide in Matrixyl 3000” — its standalone identity is less recognized than in the formulator community. Community members building DIY collagen-support serums often include it alongside the full Matrixyl 3000 blend, GHK-Cu, and other matrikine peptides. This “more is more” stacking approach is understandable in motivation but introduces redundancy — multiple GHK-sequence-based compounds addressing the same signaling pathway with diminishing marginal returns at saturation. For a detailed examination of peptide stacking logic and where redundancy enters, see the More Is Not Always More guide.

Frequently Asked Questions

Q: What is the difference between palmitoyl tripeptide-1 and Matrixyl 3000?

A: Palmitoyl tripeptide-1 is one of the two active peptides in Matrixyl 3000. Matrixyl 3000 is a blend of palmitoyl tripeptide-1 (collagen-stimulating matrikine) and palmitoyl tetrapeptide-7/Rigin (anti-inflammatory, IL-6 suppression). A product containing palmitoyl tripeptide-1 alone has the collagen-stimulating component but not the anti-inflammatory component of the full Matrixyl 3000 blend. If your formulation already contains strong anti-inflammatory actives (niacinamide, centella asiatica, azelaic acid), standalone palmitoyl tripeptide-1 may be sufficient; if not, the full Matrixyl 3000 combination adds meaningful value.

Q: Does palmitoyl tripeptide-1 have clinical trial evidence?

A: Most clinical evidence comes from Matrixyl 3000 combination studies — primarily Robinson 2005 (23 women, 3% combination formulation, 60 days), which demonstrated significant wrinkle reduction versus vehicle control. This is evidence for the combination, not for palmitoyl tripeptide-1 in isolation. Standalone clinical trial data with the design quality of the original Matrixyl 2003 study does not exist for palmitoyl tripeptide-1 specifically. The mechanistic and in vitro evidence is strong and independently characterized through Pickart's GHK research.

Q: Can palmitoyl tripeptide-1 be used with microneedling?

A: Yes, and the rationale is mechanistically sound. The target cells — dermal fibroblasts — are at 0.5–2.0 mm depth, directly accessible to standard microneedling devices. Bypassing the stratum corneum barrier should meaningfully increase peptide delivery to the relevant cell population. No palmitoyl tripeptide-1-specific microneedling clinical trial exists. The same sterility concern applies as for all cosmetic-grade microneedling: source material is not manufactured to pharmaceutical sterility standards, and introducing non-sterile solutions below the skin barrier carries infection risk.

Q: Is it worth using palmitoyl tripeptide-1 alongside GHK-Cu in the same formulation?

A: The combination has some mechanistic logic — palmitoyl tripeptide-1 uses lipophilic topical delivery to signal collagen synthesis, while GHK-Cu additionally activates copper-dependent wound-healing enzymes. The mechanisms are related but not fully redundant. However, stacking multiple GHK-sequence compounds in the same formulation creates diminishing returns on the matrikine signaling pathway at saturation. A formulation containing palmitoyl tripeptide-1, GHK-Cu, and Matrixyl 3000 is addressing the same collagen-stimulating pathway three times simultaneously — mechanistically coherent in direction, but not necessarily additive in practice. See the More Is Not Always More guide for a fuller treatment of peptide stacking logic.

Q: How long does palmitoyl tripeptide-1 take to work?

A: Based on the Matrixyl 3000 combination study, measurable outcomes were seen at 60 days with twice-daily application. Collagen synthesis is a slow structural process — meaningful changes accumulate over 8–12 weeks of consistent use. Unlike NMJ-targeting peptides (argireline, Syn-Ake) whose effects reverse rapidly on discontinuation, collagen-stimulating matrikines may produce somewhat more durable structural changes, though this hasn't been formally studied for this specific compound.

Q: Is palmitoyl tripeptide-1 safe?

A: Topical palmitoyl tripeptide-1 has an excellent safety profile, consistent with the broader Matrixyl 3000 record across decades of widespread commercial use. Contact sensitization is rare. No serious adverse events have been reported. For microneedling use, sterility of source material is the primary risk — cosmetic-grade powder is not manufactured to pharmaceutical standards. For SC injection, there is no safety data, and the palmitoyl chemistry is designed for topical delivery, not systemic distribution.

Palmitoyl tripeptide-1 belongs to the matrikine signal peptide category alongside original Matrixyl (palmitoyl pentapeptide-4), which shares a different procollagen-derived sequence but the same general mechanism. Its closest structural relative in the Cluster G group is GHK-Cu — same GHK tripeptide, different chemistry and mechanism. In the context of Matrixyl 3000, palmitoyl tetrapeptide-7 (Rigin) is its combination partner, providing the anti-inflammatory complement to palmitoyl tripeptide-1’s collagen-stimulating signal. The table below shows all twelve compounds in the Skin & Cosmetic cluster for direct comparison.

Edit
Compound Type Primary Target Half-Life FDA Status WADA Status Evidence Tier Skin Target / Mechanism Typical Concentration Route Key Differentiator
Argireline (Acetyl Hexapeptide-3) Synthetic hexapeptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2, SNAP-25 modulator) SNARE complex disruption / Botox-like wrinkle reduction (proposed) ~2–4 hours (topical; serum stability uncertain) Not FDA-approved (cosmetic ingredient, GRAS status for topical use) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Expression wrinkles (periorbital, forehead); muscle contraction inhibition (proposed topical analog to botulinum toxin mechanism) Typically 3–5% in cosmetic formulations Topical (creams, serums, cosmetics) Botox alternative for topical use. Synthetic SNARE inhibitor design. Limited published clinical efficacy vs. marketing claims
Matrixyl (Palmitoyl Pentapeptide-4) Synthetic pentapeptide conjugated to palmitic acid (Pal-GVQPR, collagen-stimulating) Procollagen upregulation (TGF-β pathway proposed); collagen I/III synthesis ~1–3 hours (topical) Not FDA-approved (cosmetic ingredient) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Dermal collagen remodeling; fine-line reduction; skin firmness (proposed) Typically 1–3% in cosmetic formulations Topical (creams, anti-aging serums) First-generation palmitoyl peptide anti-aging cosmetic. Synthetic TGF-β mimic. Limited independent clinical validation
Matrixyl 3000 (Palmitoyl Tripeptide-1 + Palmitoyl Tetrapeptide-7 Blend) Synthetic blend of two palmitoyl peptides (Pal-GHK + Pal-GHKGQ, synergistic collagen/elastin remodeling) Dual collagen + elastin upregulation (proposed; broader TGF-β pathway activation) ~1–3 hours (topical) Not FDA-approved (cosmetic ingredient blend) Not WADA-listed (topical cosmetic peptide blend) Tier 4 — Preclinical Only Dermal collagen and elastin remodeling; wrinkle depth and skin texture improvement (proposed) Typically 1–3% in cosmetic formulations (as synergistic blend) Topical (creams, serums, moisturizers) Second-generation peptide blend (Matrixyl + Palmitoyl Tetrapeptide-7). Synergistic formulation strategy. Limited peer-review studies
Snap-8 (Acetyl Octapeptide-3) Synthetic octapeptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-Gly-Gly-NH2, extended Argireline analog) Extended SNARE modulation / Acetylcholine inhibition (proposed Botox alternative) ~2–4 hours (topical) Not FDA-approved (cosmetic ingredient) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Expression wrinkles (dynamic lines); neuromuscular junction relaxation analog (topical) Typically 2–5% in cosmetic formulations Topical (creams, serums, eye patches) Extended Argireline with two additional amino acids. Claimed improved potency vs. Argireline. Minimal peer-reviewed efficacy data
Leuphasyl (Hexapeptide-11) Synthetic hexapeptide (Palmitoyl-Pro-Asn-Thr-Asn-Leu-Ala, matrix metalloproteinase inhibitor proposed) MMP inhibition (skin-matrix degradation prevention); collagen preservation ~2–3 hours (topical) Not FDA-approved (cosmetic ingredient) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Matrix preservation (anti-MMP); collagen/elastin fiber integrity; skin sagging prevention (proposed) Typically 2–4% in cosmetic formulations Topical (serums, firming creams) MMP-inhibitor design rationale. Alternative to collagen-upregulating peptides. Limited cosmetic industry data
Palmitoyl Tripeptide-1 (Pal-GHK) Synthetic tripeptide conjugated to palmitic acid (Pal-Gly-His-Lys, copper-chelating glycine-histidine-lysine) Copper chelation (collagen synthesis via Lox upregulation); wound healing reactivation ~1–2 hours (topical) Not FDA-approved (cosmetic ingredient, component of Matrixyl 3000) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Dermal collagen cross-linking; elastin remodeling; scar remodeling (proposed) Typically 1–2% in cosmetic formulations (as Matrixyl 3000 blend component) Topical (anti-aging serums, creams) Core component of Matrixyl and Matrixyl 3000. Copper-dependent mechanism. Palmitoyl modification enhances skin penetration
Palmitoyl Tetrapeptide-7 (Pal-GHKGQ) Synthetic tetrapeptide conjugated to palmitic acid (Pal-Gly-His-Lys-Gly-Gln, extended GHK variant with elastin-targeting residues) Elastin upregulation; integrin signaling activation (proposed); elastin-specific pathway ~1–3 hours (topical) Not FDA-approved (cosmetic ingredient, component of Matrixyl 3000) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Elastin remodeling (distinct from collagen pathway); skin elasticity and bounce; fine-line reduction (proposed) Typically 1–2% in cosmetic formulations (as Matrixyl 3000 blend component) Topical (anti-aging serums, firming creams) Extended GHK variant targeting elastin specifically. Synergistic with Palmitoyl Tripeptide-1 in Matrixyl 3000
Syn-Ake (Dipeptide Diethylaminobutyroyl Benzylamide Diacetate, Snake Venom Mimetic Peptide) Synthetic dipeptide-conjugate mimicking snake venom neurotoxins (synthetic neuro-blocking peptide) Neuromuscular junction analog blockade (topical snake venom mimic); acetylcholine inhibition ~2–4 hours (topical) Not FDA-approved (cosmetic ingredient) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Expression line relaxation (periorbital wrinkles); dynamic wrinkle reduction (snake venom analog mechanism topical) Typically 1–3% in cosmetic formulations Topical (eye creams, serums, patches) Snake venom analog mechanism. Branded as natural-origin alternative to botulinum toxin. Limited clinical efficacy studies
Acetyl Tetrapeptide-5 (SNAP-25 Mimic) Synthetic tetrapeptide (Ac-Glu-Glu-Met-Gln, acetylated SNARE domain fragment) SNAP-25 modulation (neuromuscular junction-like topical effect, proposed) ~1–3 hours (topical) Not FDA-approved (cosmetic ingredient) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Expression lines (wrinkle reduction, proposed Botox analog); muscle-relaxation topical effect Typically 2–5% in cosmetic formulations Topical (anti-wrinkle serums, creams) Short SNAP-25 fragment. Purported Botox alternative via topical neuromuscular effects. Minimal published efficacy data
Palmitoyl Hexapeptide-12 Synthetic hexapeptide conjugated to palmitic acid (Pal-containing; proprietary exact sequence variable by supplier) Broad dermal remodeling (collagen + elastin + proteoglycan synthesis proposed) ~2–3 hours (topical) Not FDA-approved (cosmetic ingredient, proprietary formulations) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Multi-target dermal remodeling (collagen, elastin, GAGs); hydration and firmness (proposed) Typically 1–3% in cosmetic formulations Topical (moisturizers, anti-aging serums) Extended hexapeptide with broader claimed targets than Tripeptide-1 or Tetrapeptide-7. Proprietary variations limit standardization
AHK-Cu (Copper Tripeptide: Ala-His-Lys + Cu²⁺) Synthetic tripeptide-copper complex (alanine-histidine-lysine chelated to Cu²⁺, GHK-Cu analog) Collagen synthesis (copper-dependent lysyl oxidase activation); similar mechanism to GHK-Cu topical ~1–2 hours (topical) Not FDA-approved (cosmetic ingredient) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Dermal collagen remodeling; anti-aging (collagen-dependent wrinkle reduction); scar appearance improvement Typically 0.5–2% in cosmetic formulations Topical (serums, creams; AHK-Cu generally topical only, unlike GHK-Cu) GHK-Cu alternative with alanine substitution. More stable copper complex than GHK-Cu in some formulations. Cosmetic-grade copper peptide
Tripeptide-29 (Proprietary Sequence, Collagen-Targeting Peptide) Synthetic tripeptide (exact sequence proprietary; collagen I/III targeting proposed) Collagen-specific upregulation (proprietary mechanism); dermal matrix support ~1–2 hours (topical) Not FDA-approved (cosmetic ingredient) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Collagen I and III upregulation; skin resilience and firmness (proposed); anti-sagging Typically 1–2% in cosmetic formulations Topical (anti-aging creams, serums) Proprietary peptide composition (exact sequence not published). Limited third-party efficacy studies

Summary and Key Takeaways

Palmitoyl tripeptide-1 is mechanistically one of the better-grounded cosmetic peptides in the Cluster G group — the GHK sequence has been independently characterized across decades of research, the TGF-β and integrin signaling pathways are well-established, and the in vitro evidence is more independently replicated than most proprietary cosmetic peptide sequences. Its standalone clinical evidence is limited — most human data comes from Matrixyl 3000 combination studies — but the mechanistic foundation justifies its inclusion in collagen-focused formulations, whether as a component of Matrixyl 3000 or as a standalone at 1–3%.

  • Palmitoyl tripeptide-1 (Pal-GHK) contains the GHK tripeptide sequence from collagen I, attached to a palmitoyl chain for stratum corneum penetration. It is one of the two active components of Matrixyl 3000, and is also available as a standalone ingredient.
  • It is not the same as GHK-Cu. Both share GHK but palmitoyl tripeptide-1 is palmitoylated for topical delivery without copper; GHK-Cu chelates copper as a core part of its mechanism. Related compounds, non-interchangeable.
  • Mechanism: matrikine signaling via TGF-β and integrin pathways → collagen I/III and fibronectin upregulation + potential MMP-1 inhibition. Mechanistic foundation is independently well-characterized through Pickart’s GHK research.
  • Clinical evidence is primarily from Matrixyl 3000 combination studies (Robinson 2005). Standalone clinical trial data is limited — the combination evidence is the strongest available, but does not isolate palmitoyl tripeptide-1’s individual contribution.
  • Topical use at 1–3% is evidence-supported (in combination context). Microneedling is mechanistically appropriate for dermal fibroblast targeting at relevant depths. SC injection has no evidence and bypasses the palmitoyl topical delivery mechanism.
  • For formulators: consider standalone palmitoyl tripeptide-1 when the formulation already contains strong anti-inflammatory actives; use Matrixyl 3000 (which adds Rigin’s IL-6 suppression) when no other anti-inflammatory is included.
  • Multiple GHK-sequence peptides in the same formulation (palmitoyl tripeptide-1 + GHK-Cu + Matrixyl 3000) creates mechanistic redundancy on the collagen-stimulating pathway — complementary in some ways, diminishing returns in others. See the More Is Not Always More guide.
  • WADA: not prohibited. Regulatory: cosmetic ingredient, not a drug.

The research moves fast. We read all of it so you don’t have to.

New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.

Subscribe to Peptidings Weekly

Selected References and Key Studies

  1. Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. PMID 29986520 — comprehensive GHK sequence biology review
  2. Robinson LR, et al. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. Int J Cosmet Sci. 2005;27(3):185–95. PMID 18492182 — primary Matrixyl 3000 combination clinical study
  3. Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015;2015:648108. PMID 26065009
  4. Gorouhi F, Maibach HI. Role of topical peptides in preventing or treating aged skin. Int J Cosmet Sci. 2009;31(5):327–45. PMID 19624730
  5. Schagen SK. Topical peptide treatments with effective anti-aging results. Cosmetics. 2017;4(2):16. doi:10.3390/cosmetics4020016
  6. Sederma technical dossier: Matrixyl 3000. Clinical and in vitro data on file, Croda Beauty Actives. Available at: sederma.fr

Further Reading and References

Disclaimer

This article is produced for educational and research purposes only. Peptidings does not provide medical advice, diagnosis, or treatment recommendations. Nothing in this article should be interpreted as an endorsement of any cosmetic product, formulation, or delivery method.

Palmitoyl tripeptide-1 is a cosmetic ingredient, not an FDA-approved drug. It has not been evaluated by the FDA for safety or efficacy. Matrixyl 3000® is a registered trademark of Sederma/Croda; palmitoyl tripeptide-1 is available as a generic ingredient from multiple cosmetic suppliers.

All citations link to primary sources where available. Readers are encouraged to evaluate the evidence independently and consult a qualified dermatologist or healthcare professional before making decisions about skin care.

Scroll to Top